Biosurgery is promising adjunct to the whole spectrum of topical treatment methods, in particular for debridement. Biosurgery involves natural, synthetic, or semi-synthetic materials to seal surgical incisions and wounds. Biosurgery products typically consist of natural, synthetic, or semi-synthetic materials that help seal surgical incisions and facilitate tissue repairs.
Increase in prevalence of cardiovascular diseases, growing geriatric population, rise in adoption of advanced surgical tools and devices, increase in research & development, rising health awareness, and developing healthcare infrastructure are major factors expected to propel growth of the global biosurgerymarket during the forecast period.
For instance, according to the British Heart Foundation, United Kingdom Factsheet (August 2022), more than 7.6 million people are living in the United Kingdom in 2021 with some kind of heart and circulatory diseases. Moreover, in January 2020, Terumo launched its surgical sealant named AQUABRID in the EMEA market. AQUABRID is a new surgical sealant specially developed for aortic procedures. It is safe and effective in achieving hemostasis, even when blood coagulation is inhibited during cardiac surgery.
- This report provides in-depth analysis of the global biosurgerymarket, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global biosurgerymarket based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Betatech Medical, Hemostasis LLC, CryoLife Inc., CSL Limited, Medtronic PLC, Johnson & Johnson, B.Braun Melsungen AG, Baxter International Inc., Integra Lifesciences Holdings Corporation, and Becton, Dickinson and Company (CR Bard), among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global biosurgerymarket report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biosurgerymarket.
-
- Hemostatic Agents
- Bone-graft Substitutes
- Surgical Sealants and Adhesives
- Soft-tissue Attachments
- Adhesion Barriers
- Staple Line Reinforcement
-
- Orthopedic Surgery
- General Surgery
- Neurological Surgery
- Cardiovascular Surgery
- Gynecological Surgery
- Other Applications
-
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
-
- Betatech Medical
- Hemostasis LLC
- CryoLife Inc.
- CSL Limited
- Medtronic PLC
- Johnson & Johnson
- B.Braun Melsungen AG
- Baxter International Inc.
- Integra Lifesciences Holdings Corporation
- Becton, Dickinson and Company (CR Bard)